Bellevue Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Bellevue Group’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,492,466	Closed	-$84.7M	–	232
2019 Q3	$84.7M	Buy	4,492,466 +373,660	+9%	+$4.27M	1.58%	17
2019 Q2	$48.5M	Buy	4,118,806 +2,832,058	+220%	+$34.3M	0.83%	34
2019 Q1	$17.6M	Buy	1,286,748 +162,935	+14%	+$2.11M	0.97%	33
2018 Q4	$11.5M	Buy	1,123,813 +218,559	+24%	+$2.8M	0.76%	40
2018 Q3	$15.1M	Buy	905,254 +146,290	+19%	+$2.64M	0.96%	35
2018 Q2	$12M	Buy	758,964 +58,500	+8%	+$889K	1.02%	37
2018 Q1	$8.9M	Buy	700,464 +669,864	+2,189%	+$9.69M	0.88%	45
2017 Q4	$350K	Sell	30,600 -2,400	-7%	-$26.8K	0.04%	131
2017 Q3	$404K	Hold	33,000	–	–	0.04%	129
2017 Q2	$378K	Hold	33,000	–	–	0.04%	129
2017 Q1	$686K	Hold	33,000	–	–	0.09%	113
2016 Q4	$686K	Hold	33,000	–	–	0.14%	100
2016 Q3	$1.08M	Hold	33,000	–	–	0.2%	94
2016 Q2	$824K	Hold	33,000	–	–	0.16%	101
2016 Q1	$808K	Buy	+33,000	New	+$764K	0.15%	100

Bellevue Group's ALDR Position: Q4 2019 in Review

Bellevue Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 4,492,466 shares — an estimated $84.7M sold.

Bellevue Group first reported a position in ALDR in Q1 2016 and held it in 15 quarters. The position peaked at $84.7M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Bellevue Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Bellevue Group sold 4,492,466 Alder Biopharmaceuticals shares in Q4 2019, an estimated $84.7M.
Bellevue Group first reported a position in Alder Biopharmaceuticals in Q1 2016 and held it in 15 quarters.
Bellevue Group's Alder Biopharmaceuticals position peaked at $84.7M in Q3 2019.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.